Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s ADLib® (Autonomously Diversifying Library) System and will apply the System to assessment of target proteins and lead generation of products for clinical use. Chugai will pay a contractual up-front fee to Chiome and will also pay milestones based on the results of the research. Other contractual conditions were not disclosed. Chiome and Chugai had earlier established a research collaboration agreement in July 2007. This new agreement expands the number of the targets to be addressed and seamlessly extends the term of the collaboration.